Tag: Cimerli

Cimerli (ranibizumab-eqrn), a medication for various retinal conditions, is typically given as a once-monthly treatment, but the precise dosing schedule is tailored to the specific eye disease being treated. As a biosimilar interchangeable with Lucentis, Cimerli offers consistent and effective treatment based on its approved indications.

Despite common confusion, a recent FDA approval highlights that Cimerli and Avastin are fundamentally distinct medications. To be clear, **is Cimerli the same as Avastin?** The answer is no, as Cimerli is a biosimilar drug used for retinal diseases while Avastin is an original biologic primarily for cancer treatment.